The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation

Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis

(2014) Azza AbuDagga et al.   BMC HEALTH SERVICES RESEARCH

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) Amanda R. Harrington et al.   STROKE

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

(2013) Benjamin A. Steinberg et al.   Journal of the American Heart Association

Adoption of new drugs by physicians: a survival analysis

(2012) Francisco Javier Garjón et al.   BMC HEALTH SERVICES RESEARCH

Rates of hemorrhage during warfarin therapy for atrial fibrillation

(2012) T. Gomes et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Oral Direct Factor Xa Inhibitors

(2012) Calvin H. Yeh et al.   CIRCULATION RESEARCH

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

(2012) Thomas Davidson et al.   EUROPEAN HEART JOURNAL

A systematic review of validated methods for identifying atrial fibrillation using administrative data

(2012) Paul N. Jensen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010

(2011) Jamie R. Daw et al.   HEALTH POLICY

Dabigatran in atrial fibrillation: pharmacology and clinical trials

(2011) Michael D. Ezekowitz et al.   JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY

Is new drug prescribing in primary care specialist induced?

(2009) Stefan R Florentinus et al.   BMC HEALTH SERVICES RESEARCH